sorafenib

0:06:02

HCC: Considerations in First-Line Use of Sorafenib

0:01:11

Regorafenib Vs Sorafenib in the Treatment of Liver Cancer

0:01:40

Comparing Sorafenib and Lenvatinib for the Frontline Treatment of Advanced HCC

0:02:12

Hepatocellular Carcinoma: Immunotherapy After Sorafenib

0:03:02

Using Sorafenib in Advanced HCC

0:05:40

Sorafenib Initiation After TACE in HCC

0:03:18

Managing Side Effects With Sorafenib in HCC

0:01:22

Dr. El-Khoueiry on Choosing Between Lenvatinib and Sorafenib in HCC

0:01:33

All-trans retinoic acid boosts the efficacy of sorafenib against liver cancer

0:06:50

Sorafenib: The Current Standard of Care

0:28:11

Hepatocellular Carcinoma - Molecular Approaches to Treatment

0:06:29

Sorafenib Side Effect Management in Thyroid Cancer

0:01:09

Dr. Kasper on Imatinib Versus Sorafenib in Sarcoma

0:04:35

HCC Treatment: Sorafenib + TACE

0:05:48

Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers

0:04:33

Results from a Phase III study of sorafenib and SBRT for hepatocellular carcinoma

0:05:28

Assessing Response to Sorafenib

0:08:10

Dosing Strategies With Sorafenib in HCC

0:00:58

Oncotarget: Evaluating the Role of IGF/CTP Composite Score in Sorafenib Treatment

0:04:06

Managing Toxicities with Sorafenib in HCC

0:01:41

Dr. Armaghany on Frontline Sorafenib Versus Lenvatinib in Unresectable HCC

0:01:10

AIOM 2014: Il punto su sorafenib

0:05:59

Frontline Lenvatinib vs Sorafenib in HCC

0:02:28

NRG/RTOG 1112: sorafenib vs SBRT followed by sorafenib in HCC